Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Minerva Neurosciences Inc. buy melinda

Start price
€58.52
04.04.19 / 50%
Target price
-
04.11.21
Performance (%)
-74.44%
End price
€14.96
04.01.21
Summary
This prediction ended on 04.01.21 with a price of €14.96. Massive losses of -74.44% were the result for the BUY prediction by melinda. melinda has 50% into this prediction

Minerva Neurosciences (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from neuropsychiatric disorders. With a primary emphasis on central nervous system diseases such as schizophrenia, major depressive disorder, insomnia, and Parkinson's, Minerva Neurosciences is committed to addressing unmet medical needs and advancing the understanding of the underlying biology of these conditions. Utilizing a strong research and development platform, the company aims to create a diversified portfolio of novel therapies that have the potential to significantly improve patients' quality of life and help them lead more fulfilling lives.

Performance without dividends (%)
Name 1w 1m 1y 3y
Minerva Neurosciences Inc. 2.586% 2.586% -14.388% -85.169%
iShares Core DAX® 1.804% -0.748% 13.168% 16.408%
iShares Nasdaq 100 -0.182% -3.412% 39.976% 43.502%
iShares Nikkei 225® 0.413% -7.381% 18.776% 2.874%
iShares S&P 500 0.664% -1.941% 28.141% 42.155%

According to melinda what are the pros and cons of Minerva Neurosciences Inc. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Minerva Neurosciences Inc. diskutieren
Prediction Buy
Perf. (%) -74.44%
Target price 9.020
Change
Ends at 04.11.21

| Biotechnologie | Vereinigte Staaten

22 Tage (Neurosciences Inc Minerva Minerva Neurosciences Inc Minerva meldet den Abschluss der Überbrückungs Studie eine verbesserte Formulierung von MIN-101 zur Verwendung in der Phase-3-Studie zur Behandlung der negativen Symptome bei Patienten auszuwählen leiden schizophrénie.Minerva Neurosciences Inc.

Prediction Buy
Perf. (%) -74.44%
Target price
Change
Ends at 04.11.21

Kursziel geändert auf 0,0

In the thread Trading Minerva Neurosciences Inc.
Prediction Buy
Perf. (%) -74.44%
Target price
Change
Ends at 04.11.21

Buy beendet

Stopped prediction by melinda for Minerva Neurosciences Inc.

buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€2.68
29.10.22
-
29.10.23
40.63%
30.10.23

Could be worthwhile Investment >10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€9.36
16.10.21
€20.00
16.10.22
47.44%
17.10.22

Could be worthwhile Investment >10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€57.66
02.04.19
€72.16
04.04.19
1.50%
04.04.19

Could be worthwhile Investment >10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€79.60
22.06.17
€104.00
19.12.17
-41.21%
19.12.17

Could be worthwhile Investment >10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€71.80
22.06.17
€93.81
19.12.17
-41.21%
19.12.17

Could be worthwhile Investment >10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€88.04
01.06.16
€72.16
13.06.16
-18.65%
13.06.16

Could be worthwhile Investment >10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€29.44
23.05.16
€36.08
27.05.16
173.29%
27.05.16

Could be worthwhile Investment >10% per year